Lucid Diagnostics (LUCD) Expected to Announce Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $1.30 million for the quarter.

Lucid Diagnostics Stock Down 5.0%

Shares of NASDAQ:LUCD opened at $1.13 on Monday. The company’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.12. Lucid Diagnostics has a 12-month low of $0.68 and a 12-month high of $1.80. The firm has a market cap of $119.08 million, a PE ratio of -0.99 and a beta of 1.28.

Analysts Set New Price Targets

LUCD has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Friday, April 11th. BTIG Research set a $2.00 price objective on shares of Lucid Diagnostics in a research note on Tuesday, March 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, March 26th. Finally, Ascendiant Capital Markets lifted their price objective on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the company a “buy” rating in a research note on Monday, April 21st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $3.50.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.